About Namrata Sen Chanda
Namrata is an accomplished financial journalist, with nearly a decade of experience. She specializes in interpreting news releases and framing investment strategies, and has worked with some of the leading companies in real estate, banking, insurance, mutual funds, financial research, fintech, and investment education.
After majoring in finance at college, she became a research analyst, tracking economic indicators and analyzing major global economic developments. She then went on to become a contributing author for the Market Realist, focusing on the technology sector.
Namrata has a keen interest in fundamental analysis and is passionate about educating investors about the stock market.
Recent Articles By Namrata Sen Chanda
4 Mid-Cap Stocks to Scoop Up When the Market Sells-Off Again
Rising bond yields, inflation concerns, and investors’ sector rotation have caused a significant change in market dynamics lately. Consequently, an air of uncertainty prevails and a mass sell-off may be in the cards. Thus, we think investors must now be especially judicious in picking stocks. Mid-cap stocks are particularly appealing during market dips owing to their slower response to volatility. Arrow Electronics, Inc. (ARW), Jabil Inc. (JBL), Herbalife Nutrition (HLF), and Sanderson Farms (SAFM) hold much growth potential based on their resilient business models. So, let’s take a closer look at their prospects.
3 Growth Stocks to Scoop Up During the Next Market Sell-Off
The stock markets are experiencing a phase of volatility and uncertainty. Inflation fears and a potential tech bubble burst could precipitate a deep sell-off in the near-term. However, experts say that inflationary headwinds will abate by year’s end. In this scenario, we think it best to pick up growth stocks with steady financials on every dip. Three such growth stocks that are lesser known are Gold Fields (GFI), Companhia Siderurgica Nacional (SID), and Ironwood Pharmaceuticals (IRWD). We believe they are poised to perform well in the long run, so buying them amid a sell-off could be rewarding.
Beware of These 3 Overvalued Work-From-Home Stocks
As the world slowly emerges from a public health crisis that has gripped it over the past year, the U.S. economy stands at the cusp of a return to normal. While this is a positive development, it may not bode well for companies that thrived on remote working and learning amid the pandemic. Zoom (ZM), Wix.com (WIX), and Fastly (FSLY) are three companies that are staring at an uncertain future. As a result of the strong bull run they witnessed in 2020, their valuations have become stretched. Thus, we believe it is advisable for investors to be circumspect about betting on these stocks now. Here are some details:
Buy These 3 Value Stocks as Investors Rotate Out of Big Tech
With the passage of a $1.9 trillion COVID-19 recovery plan and rising bond yields, investors have grown optimistic about a U.S. economic recovery. With this, they are now rotating away from pricey technology stocks and into fundamentally-sound value stocks. In this scenario, smart investors must invest in value stocks that have the potential to hit their fair value with the economic recovery. CVS Health (CVS), Takeda Pharmaceutical (TAK), and Cardinal Health (CAH) are three such undervalued stocks that we think could deliver solid returns in the near term.
4 Canadian Cannabis Stocks to Avoid in March
The marijuana sector in Canada and the United States is on the cusp of major growth. During the 2020 elections, New Jersey, Arizona, South Dakota, and Montana became the newest states to legalize marijuana, raising the total number of states with recreational cannabis use from 11 to 15. This bodes well for Canadian pot names that are planning a foray into the United States. However, some companies in the sector are still fundamentally weak and may not be able to benefit from industry tailwinds. Among Canadian companies that are suffering from weak financials are: Cronos Group (CRON), HEXO Corp. (HEXO), Organigram Holdings (OGI), and Juva Life (JUVAF). As such, we think they are best avoided now.
4 Warren Buffett Stocks to Add to Your Portfolio
Warren Buffett lays special emphasis on choosing companies with strong fundamentals and holding on to them. Many investors track how Buffett optimizes his investment portfolio periodically. General Motors (GM), Kroger (KR), DaVita (DVA), and Axalta Coating (AXTA) are four companies that Buffett currently owns. These names have strong positions in their respective industries and are likely to maintain momentum in the near-term. Let’s review them more closely.
4 Buy-Rated Value Stocks in the Healthcare Sector
Positive developments regarding COVID-19 vaccines, an ageing population, and optimism over cures for other serious diseases are driving healthcare stocks higher. 2020 was an outstanding year for the healthcare sector and the trend is likely to continue this year. Because the sector is at the cusp of immense growth, we think it wise to pick value stocks to benefit from long-term appreciation. AbbVie (ABBV), CVS Health (CVS), GlaxoSmithKline (GSK), and Takeda Pharmaceutical (TAK) are four undervalued stocks that we believe have attractive growth prospects. Read on.
3 Semiconductor Stocks Outperforming NVIDIA in 2021
In 2020, massive demand for technology-related products and services drove semiconductor stocks higher. Nvidia Inc. (NVDA), a leading chipmaker, benefited handsomely from the surge in chip demand. However, ongoing scrutiny of an acquisition it made has pressured its stock this year. Also, NVDA isn’t pinning its hopes on significant growth in its business from the cryptocurrency industry. Thus, we think investors seeking better semiconductor stocks should consider Intel (INTC), Micron (MU), and Skyworks Solutions (SWKS). These are companies with resilient business models and robust fundamentals, and we believe they have the potential to outshine NVDA through the remainder of 2021.
4 Canadian Marijuana Companies Up More Than 100% in 2021
Canadian marijuana companies have a strong domestic market. Nevertheless, many of them are now making inroads into the U.S. through mergers or partnerships. And because the new U.S. Presidential administration is expected to be a catalyst in accelerating the legalization of recreational marijuana, Canadian pot producers have grown increasingly optimistic about the potential for them to grow their sales in the U.S. Based on this, Canadian marijuana stocks listed on the U.S. stock exchanges have galloped lately. Four such stocks are Tilray, (TLRY), Aphria (APHA), Sundial Growers (SNDL), and Organigram Holdings (OGI). Let’s have a closer look at these names.